WO2011049043A1 - サリドマイド標的因子を利用したスクリーニング方法 - Google Patents
サリドマイド標的因子を利用したスクリーニング方法 Download PDFInfo
- Publication number
- WO2011049043A1 WO2011049043A1 PCT/JP2010/068272 JP2010068272W WO2011049043A1 WO 2011049043 A1 WO2011049043 A1 WO 2011049043A1 JP 2010068272 W JP2010068272 W JP 2010068272W WO 2011049043 A1 WO2011049043 A1 WO 2011049043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thalidomide
- crbn
- cereblon
- fragment
- substance
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Definitions
- the present invention relates to a non-teratogenic substance, for example, a pharmaceutical, a pharmaceutical additive, a food, a food additive, in particular, a non-teratogenic substance using cerebron (cereblon: CRBN) which is a thalidomide target factor or a fragment thereof.
- CRBN cerebron
- the present invention relates to a screening method for teratogenic thalidomide derivatives and a screening method for thalidomide antagonists.
- the present invention also provides a mutant CRBN that has a low binding property to thalidomide but retains the function as a component of the ubiquitin ligase complex, a nucleic acid that encodes the same, and a non-human that has been introduced and expressed.
- animals are examples of the ubiquitin ligase complex.
- thalidomide was sold as a sedative in over 40 countries, and it was often prescribed to prevent morning sickness in pregnant women. Thalidomide has become teratogenic, and it is estimated that over 1,000 to 10,000 malformations (morphogenesis disorders) have occurred when including stillbirth before its use is stopped (Cited document 1 -3). When a woman 3-8 weeks of pregnancy takes thalidomide, it causes a morphogenesis disorder in the limbs, ears, heart, and digestive tract called thalidomide embryopathy (cited references 1-3). Above all, the frequency of extremities and ears is remarkable.
- Limb abnormalities known as phocomelia are characterized by shortened arms and legs, and ear abnormalities are typified by auricia, microtia, and hearing loss. Despite considerable efforts in elucidating the cause, little is known about this outbreak. Previous studies have shown that thalidomide has oxidative stress-inducing and angiogenesis-inhibiting effects, which can be a cause of teratogenicity (references 4-5). However, some important questions remain. That is, what molecules are direct targets and how their target factors are responsible for teratogenicity.
- Non-patent Document 1 a protein called Damaged DNA Binding protein 1 (DDB1) (Non-patent Document 2, Cited Document 12), but there is no report on the relationship with thalidomide.
- DDB1 Damaged DNA Binding protein 1
- thalidomide has been increasingly used in the treatment of multiple myeloma and leprosy nodular erythema, a type of painful leprosy (cited references 2, 3, 6, 7). Although the detailed mechanism is unknown, it is known that thalidomide exerts a good effect on these diseases. However, because of the teratogenicity, thalidomide can only be used under strict control (Cited document 8). Thalidomide's teratogenic removal is highly desirable for the wider application of this useful effect.
- the present invention has been made under the above technical background, and aims to provide a means for developing a thalidomide substitute without teratogenicity while retaining the useful pharmacological action of thalidomide.
- teratogenicity is caused by thalidomide binding to CRBN and inhibiting the activity of a ubiquitin ligase complex containing CRBN as a constituent factor.
- CRBN is a causal factor of mild mental retardation in humans and that CRBN binds to DDB1, but the relationship with thalidomide was not known at all. Therefore, at the time of filing this application, it was impossible to predict that CRBN was a target factor in the teratogenicity of thalidomide.
- the teratogenicity of the thalidomide derivative can be predicted by bringing the thalidomide derivative into contact with cereblon and examining the binding property with the cereblon. If this new knowledge is further developed, the presence of thalidomide-like teratogenicity of the substance can be predicted by examining the binding properties of CRBN to all test substances, not limited to thalidomide derivatives.
- the present inventor confirmed that the amino acid residues 339 to 442 from the N-terminus of human-derived CRBN are a thalidomide binding region, and that humans in which the 384th tyrosine and the 386th tryptophan from the N-terminus are substituted with alanine. It was also found that the derived CRBN retains the function as a component of the ubiquitin ligase complex, and the binding to thalidomide decreases.
- the present invention has been completed based on the above findings.
- the present invention provides the following [1] to [11].
- the test substance is contacted with cereblon or a fragment thereof, the binding of the test substance to cereblon or a fragment thereof is evaluated, and the test substance that does not bind to cereblon or a fragment thereof, or the binding ability to cerebrone or a fragment thereof is greater than thalidomide
- a screening method for a non-teratogenic substance characterized by selecting a test substance having a lower value.
- the test substance is represented by the general formula (1)
- a case where X is R 5 -R 7 and Y is R 6 -R 8 is a compound (A)
- a case where X is R 5 and Y is R 6 -R 8 Compound (B) and the case where X is R 5 and Y is R 8 are referred to as Compound (C)
- R 1 , R 2 , R 3 and R 4 are —H; —OH; ⁇ O; linear and branched alkanes, alkenes, alkynes; cyclic alkanes, alkenes and alkynes; cyclic and acyclic alkanes, Alkenes and alkyne combinations; alcohols, aldehydes, ketones, carboxylic acids, esters, or cyclic, acyclic ether moieties in
- the cereblon fragment has the amino acid sequence from 339 to 442 from the N-terminal in the amino acid sequence shown in SEQ ID NO: 7, and substitution or deletion of one or more amino acid residues in other amino acid sequences And / or the method for screening a non-teratogenic substance according to any one of [1] to [3], which has an added amino acid sequence.
- a step of bringing a test substance into contact with cereblon or a fragment thereof, examining binding properties of the test substance with cereblon or a fragment thereof, and selecting a test substance that binds to cereblon or a fragment thereof, and a test substance selected in the above step A method for screening an antagonist of a teratogenic substance, comprising the step of: i) teratogenicity, or ii) a substance that reduces an activity inhibitory action of a ubiquitin ligase complex containing cereblon.
- the non-teratogenic substance obtained by the screening method of the present invention can predict the presence or absence of thalidomide-like teratogenicity, and the non-teratogenic thalidomide derivative is useful as a substitute for thalidomide.
- the thalidomide antagonist obtained by the screening method of the present invention has a function of reducing the teratogenic risk due to thalidomide.
- An animal in which a nucleic acid encoding the mutant CRBN of the present invention has been introduced and expressed as a gene is resistant to thalidomide teratogenicity, and thus is useful for evaluating thalidomide pharmacological effects.
- Thalidomide-binding protein was purified from HeLa cell extract using thalidomide-immobilized beads (+) or control beads (-). Protein bound to thalidomide-immobilized beads is eluted by addition of thalidomide. The eluted protein was subjected to silver staining after electrophoresis (upper figure). An asterisk (*) is a nonspecifically bound protein. The bound proteins were identified as CRBN and DDB1 by tandem mass spectrometry and Western blot. By adding 0.3 mM thalidomide to the extract before mixing with beads, the eluted CRBN and DDB1 decreased.
- Thalidomide-immobilized beads were mixed with purified recombinant proteins CRBN-FLAG and DDB1-V5-His. Western blotting analyzed whether the protein bound to thalidomide-immobilized beads was CRBN or DDB1, and the protein bound to the beads was CRBN.
- C CRBN-FLAG and DDB1-V5-His were expressed in Sf9 cells simultaneously or alone and immunopurified using a FLAG antibody. When the purified protein was electrophoresed and stained with Coomassie, DDB1 was detected. The figure regarding the E3 complex formation by CRBN, DDB1, and Cullin 4A (Cul4A).
- E 293T cells that stably express FH-CRBN (WT, wild type) or CRBN mutant lacking the ability to bind to DDB1 ( ⁇ Mid, mutant lacking amino acids 187 to 260 of CRBN) MG132 was added and the same operation as D was performed. In cells expressing ⁇ Mid, auto-ubiquitination of CRBN mutant by MG132 treatment was suppressed. Diagram of inhibition of CRBN function by thalidomide. (A) CRBN (wild type) and CRBN mutants. The asterisk indicates alanine substitution. (B) GST-CRBN wild type or mutant protein was mixed with thalidomide-immobilized beads, and bound CRBN mutants were detected by silver staining.
- zcrbn AMO zcrbn antisense morpholinooligonucleotide alone or with zcrbn mRNA was injected into 1-cell stage embryos.
- zcrbn AMO inhibited the development of pleural folds and otocysts, but it could be mitigated by co-introduction of zcrbn mRNA.
- G to I zcul4a AMO alone or with zcul4a mRNA was injected into 1 cell stage embryos.
- zcul4a AMO inhibited the development of pleural and otic vesicles, but it was mitigated by co-introduction of zcul4a mRNA
- a and C 75 hpf embryos were fixed and stained with Alcian blue.
- the upper figure is the dorsal view of the embryo.
- the figure below is an enlarged view of the chest.
- the pectoral fin is indicated by arrowhead.
- B, E and H Enlarged view of the otocyst at 30hpf.
- D and G 48hpf embryos were subjected to in situ hybridization with fgf8a (fibroblast growth factor 8a) and shh (sonic hedgehog) probes. An enlarged view of fin buds is shown.
- C and D The embryos at 48hpf were subjected to in situ hybridization with fgf8 or shh probes. The figure shows an enlarged photo of the fins. uninj.
- thalidomide mitigated the decrease in fgf8a expression.
- a and B Structure of FR259625 which is thalidomide and its derivatives.
- C Flow of thalidomide immobilization reaction. Diagram of purification of thalidomide binding factor from various cell types. Thalidomide-immobilized beads were added to the cell type extract as shown in the figure and reacted. DDB1 and CRBN fractions eluted with thalidomide were detected by Western blotting. In competitive inhibition, 0.3 mM thalidomide is added to the extract before binding to the beads.
- CRBN and DDB1 were detected as thalidomide-binding proteins in various cell types.
- a 293T cell line stably expressing FH-CRBN or a control cell (mock) extract was immunoprecipitated with a FLAG antibody, and subjected to SDS-PAGE and silver staining.
- DDB1 co-precipitated with CRBN.
- the FH-CRBN complex purified from the 293T cell line that stably expresses FH-CRBN is self-ubiquitinated in the presence or absence of GST-ubiquitin, Ubal (equivalent to E1), UbcH5b (equivalent to E2), or ATP. Reaction was performed. The reaction solution was subjected to Western blotting using the antibody shown in the figure. Mock is a FLAG-purified fraction from control cells. Self-ubiquitination was observed in the presence of CRBN complex. The figure which shows the relationship between knockdown of DDB1 and CRBN protein amount.
- the extract obtained from 293T cells introduced with DDB1 siRNA or control siRNA and thalidomide-immobilized beads were mixed, and DDB1 or ⁇ -actin in input and CRBN bound to the beads were analyzed by Western blotting.
- CRBN binding to thalidomide decreased with the decrease of DDB1 expression.
- A Diagram of CRBN (wild type) and CRBN-deficient mutants.
- B FH-CRBN (wild type) and its deletion mutant were expressed in 293T cells and immunoprecipitated with FLAG antibody.
- CRBN and its mutants and bound endogenous DDB1 were analyzed by Western blotting.
- FIG. 1 The figure which shows the expression of zcrbn and zcul4a in a zebrafish embryo. The expression of zcrbn and zcul4a in 48hpf embryos was verified by whole mount in situ hybridization.
- A zcrbn is highly expressed in head blood vessels, pectoral fins, and brain. It is a side view and the left is the front.
- B zcrbn expression in the otocyst at 48 hpf. (At OV, arrowhead) Dorsal view, front part is head.
- E Expression of fgf8 in 48hpf embryos as a control. It is expressed in the midbrain / hindbrain boundary and hindbrain. The scale bar is 0.2mm. The figure about the biochemical analysis result of zCrbn.
- Thalidomide-immobilized beads were mixed and reacted with the 293T cell extract expressing FH-zCrbn. The bound protein was eluted with thalidomide and analyzed by Western blotting. zCrbn bound to thalidomide.
- B The 293T cell extract expressing FH-zCrbn was immunoprecipitated with a FLAG antibody, and the binding of DDB1 was verified by Western blotting. Human endogenous DDB1 was found to bind.
- C Thalidomide-immobilized beads were mixed with the 293T cell extract expressing FLAG-zCrbn (wild type) or FLAG-zCrbn YW / AA.
- a decrease in fgf8 expression is involved.
- the 293T cell extract was mixed with thalidomide-immobilized beads. Factors bound to the beads were eluted with thalidomide or an equal amount of phthalimide, and CRBN and DDB1 in the eluted fraction were analyzed by Western blotting.
- the thalidomide-immobilized beads were mixed with the HEK293T cell extract, washed, and the bound protein was eluted with a thalidomide derivative.
- the CRBN in the eluted fraction was subjected to Western blot.
- Vehicle in the figure indicates DMSO.
- SDS-Boil is a fraction obtained by heating washed beads to 98.5 ° C in a buffer containing 2% SDS to dissociate CRBN bound to thalidomide-immobilized beads.
- CRBN was eluted by thalidomide and glutarimide, but was not eluted by addition of phthalimide and 5-Hydroxy- (2,6-diisopropylphenyl) -1H-isoindole-1,3-dione (5HPP-33).
- Thalidomide or 5HPP-33 was added to KMS-12 cells to a final concentration of 100 ⁇ M. The cells were cultured for 48 hours in an incubator set at 37 ° C. and 5% CO 2.
- test substance is brought into contact with CRBN or a fragment thereof, and the binding of the test substance to CRBN or a fragment thereof is evaluated.
- a test substance that does not bind to a fragment, or a test substance that binds to CRBN or a fragment thereof lower than thalidomide is selected.
- Select test substances whose binding to CRBN etc. is lower than that of thalidomide for example, by conducting a control experiment using thalidomide instead of the test substance, and comparing the binding of the test substance with the binding of thalidomide be able to.
- CRBN is thought to be a target factor for thalidomide teratogenicity. Therefore, it is considered that a substance that does not bind to this substance or a substance that has a lower binding property than thalidomide does not have the teratogenicity of thalidomide or that the teratogenicity is reduced.
- test substance is not particularly limited, but a substance to be administered and fed to humans or other animals is preferable, and examples thereof include drugs, pharmaceutical additives, foods, food additives, or chemical substances contained therein.
- thalidomide derivatives are important. Examples of thalidomide derivatives include compounds represented by the following general formula (1).
- thalidomide derivatives 5-Hydroxy- (2,6-diisopropylphenyl) -1H-isoindole-1,3-dione (5HPP-33) has pharmacological actions such as growth inhibition of human myeloma cells. It was confirmed that the binding to cereblon was quite low.
- the thalidomide derivative is preferably one having the pharmacological action of thalidomide or a known thalidomide derivative.
- the pharmacological action of thalidomide includes (i) suppression of angiogenesis induced by bFGF, (ii) suppression of TNF- ⁇ production from LPS-stimulated human monocytes, tumor cells such as human myeloma cells and human bone marrow stromal Suppression of IL-6 production enhanced by co-culture with cells, (iii) increase in the number of natural killer cells in the peripheral blood of patients with multiple myeloma, IL-2 and INF- ⁇ production after stimulation with T cell receptors And promotion of T cell proliferation in an IL-2 dependent manner, and (iv) induction of apoptosis and suppression of cell proliferation of tumor cells such as human myeloma cells.
- Thalidomide's disease prevention and treatment effects include sedation, leprosy treatment (specifically, treatment for leprosy nodular erythema), transplantation treatment, multiple myeloma treatment, solid cancer Examples include therapeutic action, systemic lupus erythematosus therapeutic action, multiple sclerosis therapeutic action, Behcet's disease therapeutic action, and inflammatory bowel disease (Crohn's disease and ulcerative colitis) therapeutic action.
- the pharmacological actions of known thalidomide derivatives include the treatment of multiple myeloma with lenalidomide, the treatment of myeloma dysplasia syndrome (MDS), the treatment of multiple myeloma with pomalidomide, the treatment of myelofibrosis
- MDS myeloma dysplasia syndrome
- pomalidomide the treatment of multiple myeloma with pomalidomide
- myelofibrosis The action can be exemplified.
- CRBN is a known protein, and the base sequence of the gene encoding it (CRBN gene) is also published on the database.
- the base sequence of CRBN gene derived from human the base sequence of CRBN gene derived from mouse, the base sequence of CRBN gene derived from rat, and the base sequence of CRBN gene derived from zebrafish are Gene ID: 51185, Gene ID: It is registered in Entre Gene with 58799, Gene ID: 297498, and Gene ID: 445491.
- the CRBN or CRBN gene to be used may be natural, but consists of an amino acid sequence in which one or several amino acid deletions, substitutions or additions are made in the amino acid sequence of the natural CRBN, and an active ubiquitin ligase complex. Mutant CRBN capable of forming a gene or a gene encoding the same may be used.
- the present inventor has identified a thalidomide binding region in human-derived CRBN. Therefore, even when a CRBN fragment containing a thalidomide-binding region is used instead of CRBN, the binding property can be evaluated.
- the thalidomide-binding region include a 104 amino acid region on the C-terminal side of human-derived CRBN.
- the region corresponding to the 104 amino acid region on the C-terminal side ie, the 104 amino acid region on the C-terminal side of human-derived CRBN when aligned based on amino acid identity
- the CRBN fragment has the amino acid sequence of 339 to 442 from the N-terminal in the amino acid sequence of human-derived CRBN shown in SEQ ID NO: 7, and substitution of one or more amino acid residues in the other amino acid sequences. Examples include those having amino acid sequences that have been deleted and / or added, and fragments of CRBN derived from various organisms corresponding to the human CRBN fragments. In addition, CRBN and fragments thereof may be fused with other proteins.
- the CRBN or fragment thereof used in the present invention may be any of the above-mentioned various organism-derived CRBNs, mutant CRBNs or fragments thereof, but the present invention provides a thalidomide derivative that is not teratogenic to humans. Therefore, it is preferable to use human-derived CRBN or a fragment thereof.
- the carrier is not particularly limited as long as it can fix CRBN or a fragment thereof, but a particulate one is preferable, and one having magnetism is preferable.
- preferred carriers include magnetic nanobeads having an organic polymer film.
- the particle size of the magnetic nanobead having an organic polymer film is not particularly limited, but is preferably 1-500 nm, and more preferably 20-300 nm.
- the organic polymer include GMA, a copolymer of GMA and styrene, (poly) methacrylic acid, and (poly) acrylic acid.
- magnetic nanobeads having an organic polymer film include SG beads (kawaguchi et al. Nucleic Acids Research 1989, 17: 6229-6240), FG beads (Nishio et al. Colloids and Surfaces B: Biointerfaces 2008, 64: 162-169) , Dynabeads, Adembeads, nanomag, etc.
- the binding evaluation of thalidomide derivatives to CRBN can be performed by a conventional method.
- the binding can be evaluated by surface plasmon resonance by BIAcore, isothermal titration calorimetry (ITC), or the like.
- the screening method of the present invention is not particularly limited as long as the binding property between the test substance and CRBN or a fragment thereof can be evaluated, but can be implemented as follows, for example.
- FG beads to which thalidomide is immobilized are prepared.
- the immobilized beads are mixed with a cell extract expressing CRBN or a recombinant protein, and the mixture is kept mixed at 5 rpm at 4 ° C. for 1 hour or more.
- a buffer for example, by passing a buffer mixed with a thalidomide derivative as a test substance through beads, it is confirmed whether CRBN elution occurs.
- Examples of the detection method include western blotting, dot blotting, CBB staining, silver staining, and the like. In this case, thalidomide or phthalimide whose non-bonding has been confirmed is used as a control sample.
- it is possible to analyze a large number of samples by using the Target Angler series of FG bead screening equipment from Tamagawa Seiki Co., Ltd.
- the screening method for teratogenic substance antagonists of the present invention comprises contacting a test substance with CRBN or a fragment thereof, etc., and whether the test substance binds to CRBN or a fragment thereof.
- the antagonist of a teratogenic substance such as thalidomide obtained by the above method inhibits the binding of the teratogenic substance to CRBN. Therefore, when taking a teratogenic substance such as thalidomide or a derivative thereof, the risk of teratogenicity can be reduced by using this antagonist together.
- the first step that is, the step of contacting a test substance with CRBN or a fragment thereof, evaluating whether the test substance binds to CRBN or a fragment thereof, and selecting a test substance that binds to CRBN or a fragment thereof, It can be performed in the same manner as the screening method of 1).
- the substance selected in the first half of the process is not an agonist but an antagonist, the substance should have a function to reduce the action of teratogenic substances such as thalidomide. Therefore, it is possible to select an antagonist of a teratogenic substance by evaluating whether teratogenicity or the activity inhibitory action of a ubiquitin ligase complex containing CRBN is reduced.
- Examples of the action of thalidomide include the conventionally known teratogenicity and the activity inhibitory action of the ubiquitin ligase complex that has been clarified by the present inventors.
- Whether or not to reduce the action of thalidomide can be confirmed by comparing the action of thalidomide in the presence and absence of the test substance.
- the screening method for the teratogenic substance antagonist of the present invention is not particularly limited, and can be carried out, for example, as follows.
- thalidomide and antagonist candidates Screening using zebrafish For zebrafish embryos whose eggshells have been removed, thalidomide and antagonist candidates are bathed. It can be said to be an antagonist if abnormalities are alleviated with respect to otocyst and fin formation compared to thalidomide alone.
- mutant CRBN of the present invention is characterized by having the following amino acid substitutions (a) and / or (b):
- the amino acid corresponding to the 384th tyrosine from the N-terminal in CRBN derived from human refers to the N of CRBN derived from human when aligned based on amino acid identity, as shown in FIG. It means the amino acid matching the 384th tyrosine from the end.
- the “amino acid corresponding to the 386th tryptophan from the N-terminal in CRBN derived from human” refers to the 386th amino acid from the N-terminal of CRBN derived from human when aligned based on amino acid identity. Means the amino acid corresponding to tryptophan.
- the 363th tryptophan from the N-terminal As shown in FIG. 12, in the CRBN derived from the mouse, the 363th tryptophan from the N-terminal, the CRBN derived from the zebrafish from the N-terminal, the 376th tryptophan, the CRBN derived from Drosophila, the 519th tryptophan from the N-terminal, derived from Arabidopsis thaliana This is the 506th tryptophan in the CRBN.
- the introduction and expression of a nucleic acid encoding a mutant CRBN into an animal can be performed according to a conventional method. For example, it can be carried out by constructing an expression vector containing DNA encoding a mutant CRBN and introducing it into a fertilized egg of an animal.
- the animal into which the nucleic acid is introduced is not particularly limited as long as it is an animal other than human, and for example, zebrafish, chicken, mouse, rabbit and the like can be used.
- the mutant CRBN of the present invention retains ubiquitin ligase activity but does not bind to thalidomide. For this reason, animals that have been introduced and expressed with a nucleic acid encoding this mutant CRBN become resistant to the teratogenicity of thalidomide.
- An animal into which a nucleic acid encoding a mutant CRBN has been introduced and expressed can be used for applications such as pharmacological analysis other than teratogenicity.
- Rabbits and chickens introduced with mutant CRBN have teratogenic tolerance, and if thalidomide or a derivative thereof is administered, it exhibits a pharmacological action that is independent of teratogenicity. Therefore, in order to analyze thalidomide action independent of the mechanism of teratogenicity, animals introduced with this mutant CRBN are extremely useful.
- Example 1 Binding of thalidomide to CRBN and DDB1
- FG beads which are magnetic fine particles
- FR259625 a thalidomide derivative to which a carboxyl group was added, was covalently immobilized on FG beads (FIG. 6), mixed with human HeLa cell extract, and incubated. Thereafter, washing was performed, and the binding factor was selectively eluted by using free thalidomide.
- Example 2 Formation of E3 complex by CRBN, DDB1, and Cul4A
- the human CRBN gene was originally reported as a candidate factor for autosomal recessive mild mental retardation (cited document 11), 442 amino acids. Encodes a protein consisting of This protein is evolutionarily well conserved and exists from plants to humans. Although recent proteomic analysis has reported that CRBN binds to DDB1 (Cited document 12), the functional relationship has not been clarified, and the biological function of CRBN is hardly known.
- the present inventor conducted a biochemical analysis in order to investigate the effect of thalidomide on the CRBN function.
- a 293T cell line stably expressing FH-CRBN was prepared, and CRBN binding protein was clarified by immunoaffinity purification using FLAG antibody from the cell extract. Silver staining of the purified product revealed that CRBN was bound to DDB1 at a molar ratio of approximately 1: 1 (Fig. 8). According to immunostaining ( Figure 2A), CRBN and DDB1 were mainly present in the nucleus. This result suggests that they have important functions in the nucleus. DDB1 has been reported to form E3 ubiquitin ligase together with Cul4 (Cul4A or Cul4B), Regulator of Cullin 1 (Roc1) and substrate receptor (Cited documents 13, 14).
- the function of the E3 ubiquitin ligase is to add a polyubiquitin chain to the substrate by specifically interacting with the ubiquitin-binding enzyme (E2) (cited references 15 and 16).
- E2 acts as a scaffold protein
- Roc1 has a RING finger domain and can interact with E2.
- DDB2, CSA, SV5-V, CDT2 and AhR are known and directly bind to the substrate to mediate ubiquitination (Cited documents 13, 7-20).
- the present inventor examined whether CRBN interacts with other components of the E3 complex, and revealed that DDB1, Cul4A and Roc1 form a complex with FH-CRBN (FIG. 2B).
- CRBN is a novel substrate receptor
- CRBN is expected to compete with other substrate receptors such as DDB2 for binding to DDB1.
- DDB2 the expression level of DDB2 increased, the amount of DDB1 co-precipitated with CRBN decreased (Fig. 2C).
- CRBN may be a substrate-binding subunit of DDB1-Cul4-Roc1 E3 ubiquitin ligase.
- the present inventor decided to verify whether the CRBN complex actually has E3 ubiquitin ligase activity.
- the substrate receptor and Cul4 are known to be self-ubiquitinated in vitro.
- In-vitro ubiquitination assay using GST-tagged ubiquitin, Unal (E1), Ubal2 (E2) and CRBN complex showed that ubiquitination activity by CRBN complex was detected (Fig. 9). .
- the present inventor treated MG132, which is a proteasome inhibitor, on 293T cells in which FH-CRBN was expressed.
- CRBN self-ubiquitination was detected in the presence of MG132, and the ubiquitination was found to be reduced by suppressing the expression of Cul4A with siRNA (FIG. 2D).
- the expression level of CRBN was decreased in siRNA of DDB1 (Fig. 10), and the effect of CRDB self-ubiquitination due to suppression of DDB1 expression could not be analyzed.
- DDB1 is functionally related to CRBN.
- CRBN is functionally a subunit of E3 ubiquitin ligase and undergoes Cul4A and DDB1-dependent self-ubiquitination.
- Example 3 Inhibition of CRBN function by thalidomide
- the present inventor has the ability to form an E3 complex while being non-thalidomide-binding.
- an N-terminal deletion mutant and a C-terminal deletion mutant were prepared, and the thalidomide-binding region was examined.
- Homology analysis of many CRBN homologues from Arabidopsis thaliana to humans revealed that the C-terminal side is highly conserved (Fig. 12).
- Fig. 12 We thought that evolutionarily well-conserved amino acids might be important for binding to thalidomide, and made several point mutants.
- mutants in which two amino acids, Y384 or W386, were substituted with alanine had reduced thalidomide-binding ability (FIG. 3C).
- Y384A / W386A a mutant in which two residues called CRBN YW / AA were substituted at the same time
- the present inventor examined whether this CRBN YW / AA retains activity. Intracellular localization was not different between the wild type and this mutant.
- CRBN YW / AA formed an E3 complex as well as wild-type CRBN, and retained its function.
- the present inventors examined whether thalidomide inhibits ubiquitination in the E3 complex containing CRBN.
- FH-CRBN or FH-CRBN on 293T cells YW / AA was stably expressed and treated with MG132 and a pharmacologically relevant amount of thalidomide (10, 30, 100 ⁇ M).
- Auto-ubiquitination of wild-type CRBN was strongly inhibited by thalidomide, but auto-ubiquitination of CRBN YW / AA was not inhibited by thalidomide (FIG. 3G). Therefore, it was suggested that thalidomide inhibits its E3 function by binding to CRBN.
- CRBN as a target of thalidomide in vivo
- the present inventor decided to verify the role of CRBN in thalidomide teratogenicity using an animal model. Although thalidomide does not exhibit teratogenicity in mice, it exhibits in rabbits and chickens (Cited documents 1-3).
- the present inventor adopted zebrafish (Danio rerio) as a model for the following reasons. (i) Easy to observe due to its rapid development and clear body (ii) Gene repression is relatively easy (Cited document 21) (iii) Zebrafish is suitable in pharmacotoxicological science (Cited document 22).
- thalidomide also shows teratogenicity in zebrafish, but in recent years, it has been found that thalidomide causes angiogenesis inhibition in zebrafish (cited document 23). We thought that thalidomide also shows teratogenicity in zebrafish.
- zcrbn CRBN ortholog (equivalent) in zebrafish.
- This gene product is about 70% conservative with CRBN in humans.
- the inventor first analyzed the expression pattern of zcrbn mRNA and revealed that zcrbn was expressed in the brain, head blood vessels, ears, and thorax at 48hpf (Fig. 13).
- zCrbn bound to thalidomide and human DDB1 FIG. 14
- the analysis results in human cell systems are considered to be effective for zebrafish.
- the influence of zCrbn on the early development of zebrafish was analyzed.
- Example 5 Molecular mechanism of thalidomide teratogenicity Since the relationship between thalidomide and CRBN was found, the present inventor determined whether or not the ubiquitin ligase complex containing CRBN is involved in teratogenicity by suppressing the expression of zCul4A. Verified. zcul4a mRNA is strongly expressed in the brain and fins (Fig. 13). As expected, zcul4a AMO caused otic vesicle and fin abnormalities (FIGS. 4G-I).
- Embryos with suppressed expression of zCul4a at 27hpf had a marked decrease in otocyst size (40% of control size) and were partially rescued by the introduction of zcul4a mRNA. The partial relief may be because zcul4a AMO was too powerful.
- Fgf8 is a factor expressed in AER (apical ectodermal ridge) in limbs and fins, and is essential for the extension of limbs and fins along the perspective axis.
- AER anterior ectodermal ridge
- 293T cell extract was mixed with thalidomide-immobilized beads, and then washed. Factors bound to thalidomide were eluted using thalidomide or phthalimide. CRBN and DDB1 in the eluted fraction were analyzed by Western blotting. CRBN and DDB1 were detected from the elution fraction of thalidomide, but these proteins were not detected from the elution fraction of phthalimide (Phthal) (FIG. 16).
- Example 7 Examination of binding between thalidomide derivative and CRBN 293T cell extract was mixed with thalidomide-immobilized beads and reacted for 2 hours. Then 0.5% NP-40 lysis buffer After washing three times with (Tris-HCl pH 8, 150 mM NaCl, 0.5% NP-40), 0.1-1 mM thalidomide, phthalimide, glutarimide, or 5HPP-33 (the structural formula of each compound is shown in FIG. CRBN was eluted by mixing with 0.5% NP-40 lysis buffer containing 1) for 1 hour. The obtained eluted fraction was analyzed by SDS-PAGE followed by Western blotting for CRBN antibody. The result is shown in FIG.
- Example 8 Growth inhibition test on multiple myeloma cells The growth inhibitory action of thalidomide and 5HPP-33 on multiple myeloma cells Kms12 was examined.
- RPMI Medium 1640 (10% FBS) was used for culture of multiple myeloma cells Kms12. When each drug treatment was performed, Kms12 was adjusted to 2 ⁇ 10 5 cells per ml, and 2 ml was dispensed into 2 ml eppendorf tubes.
- DMSO dimethyl sulfoxide
- GloMax-Multi + Detection System (promega) was used for measuring the 450 nm absorbance proportional to the cell number.
- Kms12 1 ⁇ 10 6 , 3 ⁇ 10 5 , 1 ⁇ 10 5 cells per ml was used.
- the number of cells at the time of solvent treatment was defined as 100, and the number of cells at the time of drug addition was expressed as a relative value. The relative value of the number of cells after 48 hours of culture is shown in FIG.
- 5HPP-33 showed a strong growth inhibitory action against multiple myeloma cells Kms12. As shown in Example 7, the binding property of 5HPP-33 to CRBN is low. Therefore, the growth inhibitory action of 5HPP-33 is considered to be unrelated to the binding with CRBN.
- CRBN CRBN and DDB2, a well-known substrate receptor, bind competitively with DDB1.
- CRBN is self-ubiquitinated like other substrate receptors. Many substrate receptors, including DDB2, have the WDXR structure (motif) (cited references 11, 19). On the other hand, a few of the substrate receptors lack it (cited references 13, 18). CRBN doesn't have a clear WDXR motif, so it seems like the latter type. Supporting the above idea is that CRBN and Cul4A expression suppression by zebrafish yielded similar results.
- Thalidomide's mechanism of action is multifaceted and multifaceted and is not completely understood. It is considered that thalidomide's immunomodulatory action and angiogenesis inhibitory action are involved in the therapeutic effect or teratogenicity for leprosy nodular erythema and multiple myeloma (cited references 2 and 3). In addition, thalidomide suppresses the production of multiple cytokines such as TNF-alpha and VEGF (Cited documents 30, 31), and has effects such as apoptosis induction and reactive oxygen species (ROS) production (Cited document 3). 4, 32) have been reported. Despite the accumulation of these data, the direct target of thalidomide was unknown.
- ROS reactive oxygen species
- CRBN is a major target for thalidomide teratogenicity.
- thalidomide binds directly to CRBN and inhibits the self-ubiquitination of CRBN. This is due to the inhibition of the formed ubiquitin ligase, and a similar phenomenon is observed in other ubiquitin ligases (Cited document 33).
- the abnormal development of zebrafish by thalidomide is similar to that when CRBN expression is suppressed, and is mitigated by overexpression of a CRBN mutant that is not bound to thalidomide.
- FGF8 which is essential for limb / fin extension, is a target downstream of thalidomide and CRBN complex (FIGS.
- FIG. 6 shows a diagram regarding production of thalidomide-immobilized beads.
- Thalidomide was immobilized by reacting in N, N-dimethylformamide (DMF) for 4 hours at room temperature. Unreacted amino groups in the FG beads were protected by reacting in DMF containing 20% acetic anhydride.
- the completed beads were stored at 4 ° C.
- Thalidomide-immobilized beads (0.5 mg) are 0.5% NP-40 Equilibration was performed with lysis buffer (50 mM Tris HCl pH8, 150 mM NaCl, 0.5% NP-40).
- Cell extracts are diverse and derived from HeLa, Jutkat, THP-1, U266, HUVEC, LP101, SH-SY5Y, and 293T, and their extraction methods are as described in the literature (Cited document 36). Beads were mixed with these extracts and reacted for 2 hours. The beads were washed 3 times with 0.5% NP-40 lysis buffer and then eluted with 1 mM thalidomide.
- 0.3 mM thalidomide was added to the extract prior to mixing with the beads. Whether or not phthalimide was bound was eluted with 1 mM free thalidomide, and eluted with 1 mM phthalimide instead.
- Plasmid CRBN and DDB2 cDNA were obtained from HeLa total RNA by RT-PCR. CRBN mutants were prepared by standard PCR. DDB1 cDNA was provided by Dr. Matsunaga. zCrbn and zCul4a cDNA were obtained by RT-PCR from total RNA of zebrafish embryos at 24 hpf. The following vectors were used in this study.
- pcDNA3.1-FH-N is a derivative of pcDNA3.1, in which a FLAG-HA sequence is introduced into pcDNA3.1.
- Antibody CRBN antibody is prepared from rabbits using human CRBN (65-76) as an antigen.
- FLAG M2, Sigma
- HA 3F10, Roche
- V5 V5-10, Sigma
- GST Sigma
- DDB1 Abcam
- Roc1 Zymed
- Cul4A and DDB2 were transferred, courtesy of Dr. Raychaudhuri and Dr. Matsunaga, respectively.
- RNAi Stealth RNAi oligonucleotide (Invitrogen) as shown below was used.
- DDB1 # 1 5'-CAUACCUUGAUAAUGGUGUUGUGUU-3 '(SEQ ID NO: 1)
- DDB1 # 2 5'-CAGUAAUGAACAAGGCUCCUAUGUA-3 '(SEQ ID NO: 2)
- Cul4A # 1 5'-GCAAAGCAUGUGGAUUCAAAGUUAA-3 '(SEQ ID NO: 3)
- Cul4A # 2 5'-GAAUCUCUGAUAGACAGAGACUAUA-3 '(SEQ ID NO: 4)
- Stealth RNAi negative control of low GC content Invitrogen
- Lipofectamine RNAiMAX was used to introduce 40 nM oligonucleotide into 293T cells, and the cells were collected 72 hours later.
- Embryos are obtained by natural mating (Cited document 35). Alcian blue staining, microinjection, and in situ hybridization are shown in the following section. CRBN and Cul4A (zcrbn and zcul4a) in zebrafish followed the zebrafish nomenclature committee guide.
- Thalidomide treatment of zebrafish Thalidomide was dissolved in DMSO. And it added to E3 culture medium heated at 65 degreeC beforehand so that it might become 400 micromol.
- the zebrafish embryos were dehulled and placed in thalidomide as shown below. Embryos were reacted with 2 mg / ml protease type 14 (Sigma) for 3 min at 2 hpf and washed 5 times with medium. In the process, the eggshell was shelled, but immediately replaced with thalidomide-containing medium and observed for 3 days. The thalidomide-containing medium was changed every 12 hours.
- RNA was prepared to a concentration of 600 ng / ⁇ l with nuclease-removed water immediately before use.
- Antisense oligonucleotides are as follows.
- zCrbn AMO 5'-AGAGCTGTAGCTGGTTCCCCATTTC-3 '(SEQ ID NO: 5)
- zCul4A AMO 5'-CTGGTGCTGAACATCTTCTGCCATC-3 '(SEQ ID NO: 6)
- Reference 7 S. Singhal et al., N. Engl. J. Med. 341, 1565 (1999).
- Reference 8 J. B. Zeldis, B. A. Williams, S. D. Thomas, M. E. Elsayed, Clin. Ther. 21, 319 (1999).
- Reference 9 S. Sakamoto, Y. Kabe, M. Hatakeyama, Y. Yamaguchi, H. Handa, Chem. Rec. 9, 66 (2009).
- Reference 10 S. Sakamoto, Y. Kabe, M. Hatakeyama, Y. Yamaguchi, H. Handa, Chem. Rec. 9, 66 (2009).
- Reference 11 J. J. Higgins, J. Pucilowska, R. Q.
- Reference 12 S. Angers et al., Nature 443, 590 (2006).
- Reference 13 R. Groisman et al., Cell 113, 357 (2003).
- Reference 14 F. Ohtake et al., Nature 446, 562 (2007).
- Reference 15 C. M. Pickart, Cell 116,181 (2004).
- Reference 16 M. D. Petroski, R. J. Deshaies, Nat. Rev. Mol. Cell Biol. 6, 9 (2005).
- Reference 17 K. Sugasawa et al., Cell 121, 387 (2005).
- Reference 18 R. Groisman et al., Genes Dev. 20, 1429 (2006).
- Reference 19 O.
- Reference 26 A. Streit, J. Anat. 199, 99 (2001).
- Reference 27 R. D. Riddle, R. L. Johnson, E. Laufer, C. Tabin, Cell 75, 1401 (1993).
- Reference 28 A. M. Moon, M. R. Capecchi, Nat. Genet. 26, 455 (2000).
- Reference 29 M. Lewandoski, X. Sun, G. R. Martin, Nat. Genet. 26, 460 (2000).
- Reference 30 A. L. Moreira et al., J. Exp. Med. 177, 1675 (1993).
- Reference 31 D. Gupta et al., Leukemia 15, 1950 (2001).
- Reference 32 J. Knobloch, J.
- Reference 33 T. Kamura, C. S. Brower, R. C. Conaway, J. W. Conaway, J. Biol. Chem. 277, 30388 (2002).
- Reference 34 J. M. Hansen, S. G. Gong, M. Philbert, C. Harris, Dev. Dyn. 225, 186 (2002).
- Reference 35 S. Pajni-Underwood, C. P. Wilson, C. Elder, Y. Mishina, M. Lewandoski, Development 134, 2359 (2007).
- Reference 36 H. Uga et al., Mol. Pharmacol. 70, 1832 (2006).
- Reference 37 R.
- the present invention can be used to determine whether or not a test substance has thalidomide-like teratogenicity, and can be used to develop a thalidomide substitute or a drug that suppresses thalidomide teratogenicity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
この新知見をさらに発展させれば、サリドマイド誘導体に限らず、すべての被験物質においてCRBNとの結合性を調べればその物質のサリドマイド様の催奇性の有無を予見することができる。
また、本発明者は、ヒト由来CRBNのN末端から339~442番目のアミノ酸残基がサリドマイドの結合領域であること、およびN末端から384番目のチロシン及び386番目のトリプトファンをアラニンに置換したヒト由来のCRBNは、ユビキチンリガーゼ複合体の構成因子としての機能を保持しつつ、サリドマイドとの結合性が低下することも見出した。
〔1〕被験物質をセレブロンもしくはその断片と接触させ、被験物質のセレブロンもしくはその断片に対する結合性を評価し、セレブロンもしくはその断片と結合しない被験物質、又はセレブロンもしくはその断片との結合性がサリドマイドよりも低い被験物質を選択することを特徴とする非催奇性物質のスクリーニング方法。
〔2〕被験物質が医薬であることを特徴とする〔1〕に記載の非催奇性物質のスクリーニング方法。
〔3〕被験物質が、一般式(1)
ただし、式(1)中、XがR5-R7で、YがR6-R8である場合を化合物(A)、XがR5で、YがR6-R8である場合を化合物(B)及びXがR5で、YがR8である場合を化合物(C)とし、
また、R1、R2、R3およびR4は-H;-OH;=O;直鎖および分枝アルカン、アルケン、アルキン;環式アルカン、アルケンおよびアルキン;環式ならびに非環式アルカン、アルケンおよびアルキンの組み合わせ;アルコール、アルデヒド、ケトン、カルボン酸、エステル、または環式、非環式と組み合わせたエーテル部分、あるいは環式/非環式部分の組み合わせ;アザ;アミノ;-MOnまたは-O-MOn[式中、M=Nそしてn=2;M=Sそしてn=2または3;あるいはM=Pそしてn=1-3である];そしてハロゲンから選択することができ;R5、R6、R7およびR8はそれぞれ独立して式(2)
R9は式(3)、(4)、(5)、(6)または(7)
H,-CH3,-COOH,-CONH2,-CH2)n-COOH,-(CH2)nCONH2
から選択され、n=1-4を有する部分である。
〔4〕セレブロンの断片が、配列番号7に示すアミノ酸配列において、そのN末端から339~442番目のアミノ酸配列を有し、それ以外のアミノ酸配列において1又は複数のアミノ酸残基の置換、欠失および/又は付加がなされたアミノ酸配列を有するものであることを特徴とする〔1〕~〔3〕のいずれかに記載の非催奇性物質のスクリーニング方法。
〔5〕セレブロン又はその断片が、担体に固定されていることを特徴とする〔1〕~〔4〕のいずれかに記載の非催奇性物質のスクリーニング方法。
〔6〕サリドマイド誘導体が、サリドマイド又は既知のサリドマイド誘導体のもつ薬理作用を持つものであることを特徴とする〔3〕に記載の非催奇性物質のスクリーニング方法。
〔7〕被験物質をセレブロン又はその断片と接触させ、被験物質とセレブロン又はその断片の結合性を調べ、セレブロン又はその断片と結合する被験物質を選択する工程、及び前記工程で選択された被験物質の中から、i)催奇性、又はii)セレブロンを含むユビキチンリガーゼ複合体の活性阻害作用を軽減する物質を選択する工程とを含むことを特徴とする催奇性物質のアンタゴニストのスクリーニング方法。
〔8〕セレブロン又はその断片が、担体に固定されていることを特徴とする〔7〕に記載の催奇性物質のアンタゴニストのスクリーニング方法。
〔9〕以下の(a)及び/又は(b)のアミノ酸置換を有することを特徴とする変異型セレブロン;
(a)ヒト由来のセレブロンにおけるN末端から384番目のチロシン若しくはこれに相当するアミノ酸がアラニンに置換されたもの
(b)ヒト由来のセレブロンにおけるN末端から386番目のトリプトファン若しくはこれに相当するアミノ酸がアラニンに置換されたもの。
〔10〕〔9〕に記載の変異型セレブロンをコードすることを特徴とする核酸。
〔11〕〔10〕に記載の核酸を遺伝子として導入し、発現させたことを特徴とするサリドマイド催奇性耐性非ヒト動物。
本発明の非催奇性物質のスクリーニング方法は、被験物質をCRBNもしくはその断片と接触させ、被験物質のCRBNもしくはその断片に対する結合性を評価し、CRBNもしくはその断片と結合しない被験物質、又はCRBNもしくはその断片との結合性がサリドマイドよりも低い被験物質を選択することを特徴とするものである。
CRBN等との結合性がサリドマイドよりも低い被験物質の選択は、例えば、被験物質の代わりにサリドマイドを用いた対照実験を行い、被験物質の結合性とサイリドマイドの結合性とを比較することにより行うことができる。
医薬の中では、サリドマイド誘導体が重要である。
サリドマイド誘導体としては、例えば次の一般式(1)で示される化合物があげられる。
一般式(1)
また、R1、R2、R3およびR4は-H;-OH;=O;直鎖および分枝アルカン、アルケン、アルキン;環式アルカン、アルケンおよびアルキン;環式ならびに非環式アルカン、アルケンおよびアルキンの組み合わせ;アルコール、アルデヒド、ケトン、カルボン酸、エステル、または環式、非環式と組み合わせたエーテル部分、あるいは環式/非環式部分の組み合わせ;アザ;アミノ;-MOnまたは-O-MOn[式中、M=Nそしてn=2;M=Sそしてn=2または3;あるいはM=Pそしてn=1-3である];そしてハロゲンから選択することができ;R5、R6、R7およびR8はそれぞれ独立して式(2)
R9は式(3)、(4)、(5)、(6)または(7)
H,-CH3,-COOH,-CONH2,-CH2)n-COOH,-(CH2)nCONH2
から選択され、n=1-4を有する部分である。
サリドマイド誘導体は、サリドマイドや既知のサリドマイド誘導体の持つ薬理作用を持つものが好ましい。
サリドマイドの薬理作用としては、(i)bFGFにより誘導される血管新生の抑制、(ii)LPS刺激したヒト単球からのTNF-α産生の抑制、ヒト骨髄腫細胞等の腫瘍細胞とヒト骨髄ストローマ細胞との共培養により亢進するIL-6産生の抑制、(iii)多発性骨髄腫患者の末梢血中のナチュラルキラー細胞数の増加、T細胞受容体刺激後のIL-2及びINF-γ産生の亢進、およびIL-2依存的にT細胞の増殖の促進、(iv)ヒト骨髄腫細胞などの腫瘍細胞に対してアポトーシス誘導と細胞増殖の抑制などが確認されている。
そして、サリドマイドの疾病に対する予防、治療効果としては、鎮静作用、ハンセン病治療作用(具体的には、らい性結節性紅斑の治療作用)、移植病治療作用、多発性骨髄腫治療作用、固形がん治療作用、全身性エリテマトーデス治療作用、多発性硬化症治療作用、ベーチェット病治療作用、炎症性腸疾患(クローン病や潰瘍性大腸炎)治療作用などを例示できる。既知のサリドマイド誘導体の薬理作用としては、レナリドマイド(Lenalidomide)の多発性骨髄腫治療作用、骨髄腫異形成症候群(MDS)治療作用、ポマリドマイド(Pomalidomide)の多発性骨髄腫治療作用、骨髄線維症の治療作用などを例示できる。
まずサリドマイドを固定化したFGビーズを作製する。その固定化ビーズをCRBNが発現する細胞抽出液、もしくは組み換えタンパク質と混合し、1時間以上、回転機にて5rpm、4℃で混和状態を続ける。そしてバッファーで洗浄を行った後、例えば、被験物質としてサリドマイド誘導体を混合したバッファーをビーズに通すことにより、CRBNの溶出が生じるかどうかを確認する。検出方法としては、ウェスタンブロッティング、ドットブロッティング、CBB染色、銀染色などが挙げられる。その際には、サリドマイドや、非結合が確認済みのフタルイミドが対照実験のサンプルとして用いられる。また、多摩川精機株式会社のFGビーズスクリーニング装置Target Anglerシリーズなどを用いることにより大量のサンプルの解析が可能である。
まずアミノ基もしくはカルボキシル基などの官能基をつけたCRBNをBIAcore基盤チップに固定させる。そしてその固定化チップを装着させたBIAcore3000などBIAcore計測装置(GE Healthcare)において、様々な誘導体を流入させ、その解離定数を計測する。サリドマイドやフタルイミドが対照実験として用いられる。
サリドマイド誘導体を含む溶液を試料セル中のCRBNを含む溶液へ数十回(たとえば18回)にわたって滴下する。各濃度の発生熱量をセル中における誘導体とCRBNのモル比に対してプロットすることにより相互作用の結合等温線が得られる。この結合等温線から解離定数を算出する。サリドマイドやフタルイミドが対照実験として用いられる。
本発明の催奇性物質のアンタゴニストのスクリーニング方法は、被験物質をCRBN又はその断片を混合などで接触させ、被験物質がCRBN又はその断片と結合するか否かを評価し、CRBN又はその断片と結合する被験物質を選択する工程、及び前記工程で選択された被験物質の中から、i)催奇性、又はii)CRBNを含むユビキチンリガーゼ複合体の活性阻害作用を軽減する物質を選択する工程とを含むことを特徴とするものである。
FH-CRBNを発現する293T細胞において、アンタゴニスト候補およびサリドマイドを加える。そしてその細胞抽出液におけるユビキチン化タンパク量をウェスタンブロッティングで決定する。その際に、アンタゴニストを加えることで、サリドマイド単独の場合よりユビキチン化タンパク量の減少が抑制されれば、それはアンタゴニストである。
ゼブラフィッシュ胚から卵殻を除去したものに対し、サリドマイドとアンタゴニスト候補を薬浴させる。耳胞およびヒレ形成に対して、サリドマイド単独と比べ異常が緩和されていれば、アンタゴニストといえる。
本発明の変異型CRBNは、以下の(a)及び/又は(b)のアミノ酸置換を有することを特徴とするものである。
(b)ヒト由来のCRBNにおけるN末端から386番目のトリプトファン若しくはこれに相当するアミノ酸をアラニンに置換する。
本発明において「ヒト由来のCRBNにおけるN末端から384番目のチロシンに相当するアミノ酸」とは、図12に示すように、アミノ酸の同一性に基づいて整列させた際に、ヒト由来のCRBNのN末端から384番目のチロシンと一致するアミノ酸を意味する。図12に示すように、マウス由来のCRBNではN末端から361番目のチロシン、ゼブラフィッシュ由来のCRBNではN末端から374番目のチロシン、キイロショウジョウバエ由来のCRBNではN末端から517番目のチロシン、シロイヌナズナ由来のCRBNでは504番目のチロシンが、これに該当する。同様に、本発明において「ヒト由来のCRBNにおけるN末端から386番目のトリプトファンに相当するアミノ酸」とは、アミノ酸の同一性に基づいて整列させた際に、ヒト由来のCRBNのN末端から386番目のトリプトファンと一致するアミノ酸を意味する。図12に示すように、マウス由来のCRBNではN末端から363番目のトリプトファン、ゼブラフィッシュ由来のCRBNではN末端から376番目のトリプトファン、キイロショウジョウバエ由来のCRBNではN末端から519番目のトリプトファン、シロイヌナズナ由来のCRBNでは506番目のトリプトファンが、これに該当する。
サリドマイド結合因子を精製するために、本発明者は磁性微粒子であるFGビーズを用いたアフィニティ精製を行った(引用文献9)。カルボキシル基が付加されたサリドマイド誘導体であるFR259625をFGビーズに共有結合により固定化し(図6)、ヒトHeLa細胞の抽出液と混合し、インキュベートした。その後、洗浄を行い、結合因子を遊離サリドマイドを用いることで選択的溶出を行った。そして溶出画分をSDS-PAGEおよび銀染色で解析した結果、127kDaと55kDaの二つのタンパク質が特異的に溶出されることがわかった(図1A, Lane 3)。ビーズと混合する前にあらかじめ遊離サリドマイドを抽出液に加えておくと、アフィニティ精製により得られるこれらタンパク質の収量が著しく減少した(図1A, Lane 4)。つまり、これらのタンパク質はサリドマイドに特異的に結合することが示されたのである。これら127kDaおよび55kDaのタンパク質は質量分析計により解析され、それぞれDDB1及びCRBNであることを突き止めた(表1)。これらタンパク質はウェスタンブロッティング(immunoblotting)によっても確認され(図1A)、さらに様々な細胞の抽出液からも精製されることが分かった(図7)。サリドマイドとの相互作用が直接的かどうかを調べるために、本発明者はこれらの組み換えタンパク質を精製した。サリドマイド固定化ビーズにCRBN-FLAGのみが結合し、DDB1-V5-Hisは結合しなかった(図1B)。よって、DDB1はCRBNを介してサリドマイドに間接的に結合しているのでないかと考えた。結果としてサリドマイドはCRBNに直接結合しており(図1C)、DDB1はCRBNとの相互作用を介してサリドマイドと結合しているという結論が得られた。
ヒトのCRBN遺伝子は元々は常染色体性劣性軽度精神遅滞の原因候補因子として報告されており(引用文献11)、442個のアミノ酸からなるタンパク質をコードしている。このタンパク質は進化的に良く保存されており、植物からヒトまで存在する。近年のプロテオミクス解析によりCRBNはDDB1と結合することは報告されていたが(引用文献12)、機能的な関わり合いは明らかにされておらず、CRBNの生物的機能はほとんどわかっていない。
まず本発明者はCRBN機能へのサリドマイドの効果を調べるために、生化学的な解析を行った。最初にFH-CRBNを安定的に発現させた293T細胞株を作製し、その細胞抽出液からFLAG抗体にて免疫アフィニティ精製を行うことによりCRBN結合タンパク質を明らかにすることにした。精製物に対し銀染色を行ったところCRBNはDDB1とほぼ1:1のモル比で結合していることが明らかになった(図8)。免疫染色(図2A)によるとCRBNとDDB1は主に核において存在していた。この結果は、核においてこれらが重要な機能を担っていることを示唆するものである。DDB1はCul4(Cul4AもしくはCul4B)、Regulator of Cullin 1(Roc1)そして基質レセプターとともにE3ユビキチンリガーゼを形成することが報告されている(引用文献13、14)。基本的に、E3ユビキチンリガーゼの機能とは、ユビキチン結合酵素(E2)と特異的に相互作用することにより基質にポリユビキチン鎖を付加するというものである(引用文献15,16)。Cul4は足場タンパク質として働き、Roc1はRING finger domainを持っており、E2と相互作用することが可能である。基質レセプターとしては、DDB2, CSA, SV5-V, CDT2そしてAhRが知られており、基質に直接結合してユビキチン化を仲介する(引用文献13, 7-20)。
本発明者はCRBNがE3複合体の他の構成因子と相互作用するか検証し、DDB1、Cul4A及びRoc1がFH-CRBNと複合体を形成することを明らかにした(図2B)。もしCRBNが新規の基質レセプターであるならば、DDB1への結合に対して、CRBNはDDB2といった他の基質レセプターと競い合うことが期待される。実際、DDB2の発現量を増やしていくにつれて、CRBNと共沈するDDB1の量は減少した(図2C)。つまりCRBNはDDB1-Cul4-Roc1 E3ユビキチンリガーゼの基質結合サブユニットであるかもしれないという結果が得られたのである。
CRBN-サリドマイド間の結合とその機能的重要性の基盤を明らかにするために、本発明者はサリドマイド非結合性でありながらE3複合体形成能を有するCRBN点変異体を得たいと考えた。まずN末端側欠損変異体とC末端側欠損変異体を作製し、サリドマイド結合領域を調べた結果、C末の104アミノ酸領域であることが判明した(図3A及びB)。シロイヌナズナからヒトに至るまでの多数のCRBNホモログの相同性解析からC末端側が極めて保存されていることが分かった(図12)。進化的によく保存されたアミノ酸がサリドマイドとの結合に重要なのではないかと考え、いくつかの点変異体を作製した。そして二つのアミノ酸、Y384あるいはW386をアラニンに置換した変異体はサリドマイド結合能が低下することが分かった(図3C)。さらに、Y384A/W386A (CRBN YW/AAと呼ぶ二残基同時に置換した変異体)は極めてサリドマイドとの結合能が低いことが分かった(図3C)。本発明者はこのCRBN YW/AAが活性を保持しているのか調べた。細胞内局在は野生型とこの変異体で差異は見られなかった。本発明者はこのCRBN YW/AAにおいてもDDB1、Cul4A、Roc1が免疫沈降により精製され、MG132存在下において自己ユビキチン化されることを見出した(図3E及びF)。つまりCRBN YW/AAは野生型CRBNと同様にE3複合体を形成し、機能も保持していることが分かった。
YW/AAを安定的に発現させ、MG132および薬理学的に妥当な量のサリドマイド(10,30,100μM)で処置した。野生型CRBNの自己ユビキチン化はサリドマイドにより強力に阻害されたが、CRBN YW/AAの自己ユビキチン化はサリドマイドにより阻害されなかった(図3G)。よって、サリドマイドはCRBNと結合することによりそのE3機能を阻害することが示唆された。
次に本発明者は動物モデルを用いてサリドマイド催奇性におけるCRBNの役割を検証することにした。サリドマイドはマウスにおいては催奇性を呈しないが、ウサギやニワトリにおいては発揮する(引用文献1-3)。本研究においては、本発明者はゼブラフィッシュ(Danio rerio)を以下に示す理由でモデルとして採用した。(i)発生が早くまた体が透明なことから観察が容易(ii)遺伝子抑制が比較的容易(引用文献21)(iii)ゼブラフィッシュは薬理毒性科学において適している(引用文献22)。従来、サリドマイドがゼブラフィッシュにおいても催奇性を示すかどうかは知られていなかったが、近年になりサリドマイドはゼブラフィッシュにおいて血管新生阻害を引き起こすことが分かったので(引用文献23)、本発明者はゼブラフィッシュにおいてもサリドマイドが催奇性を示すと考えた。
サリドマイドとCRBNの関連性については判明したので、本発明者はCRBNを含むユビキチンリガーゼ複合体が催奇性に関わるのかどうかを、zCul4Aを発現抑制することで、検証した。zcul4a mRNAは脳やヒレで強く発現している(図13)。予想通り、zcul4a AMOにより耳胞及びヒレの異常が生じた(図4G-I)。27hpfにおいてzCul4aを発現抑制した胚では耳胞サイズが著しく減少しており(コントロールサイズの40%)、zcul4aのmRNA導入により部分的にも救済(rescue)された。救済が部分的だったのは、zcul4a AMOの効き目が強すぎたためかもしれない。これらのことより、少なくとも、ユビキチンリガーゼ複合体が耳とヒレの発生に必要であリ、サリドマイドの標的であることが示唆された。
既知の非催奇性サリドマイド誘導体であるフタルイミドのCRBN及びDDB1に対する結合性を以下のようにして調べた。
293T細胞抽出液をサリドマイド固定化ビーズと混合し、2時間反応させた。その後、0.5%NP-40 lysis buffer
(Tris-HCl pH8, 150 mM NaCl, 0.5%NP-40)で3回洗浄し、0.1-1 mMのサリドマイド、フタルイミド、グルタルイミド、もしくは5HPP-33(各化合物の構造式を図17に示す。)を含む0.5% NP-40 lysis bufferで1時間混合することでCRBNの溶出を行った。得られた溶出画分は、SDS-PAGEの後、CRBN抗体に対するウェスタンブロッティングを行い、解析した。この結果を図18に示す。
サリドマイド及び5HPP-33の多発性骨髄腫細胞Kms12に対する増殖抑制作用を調べた。
多発性骨髄腫細胞Kms12の培養にはRPMI Medium 1640 (10% FBS) を用いた。各薬剤処理を行う場合にはKms12を1 mlあたり2 x 105細胞に調整し、2 ml eppendorf tubeに2 mlずつ分注した。添加する薬剤(サリドマイドもしくは5HPP-33)はジメチルスルホキシド(DMSO)を溶媒として最終濃度の1000倍濃度のストック溶液を作製し、2 mlの細胞懸濁液に対し2μlのストック溶液を加え、穏やかかつ十分に転倒混和させた。処理後、96 well plateに1well あたり100 μl分注したものを37℃, 5%CO2のインキュベーターで48時間培養した。処理後48時間での細胞数の測定には生細胞数測定試薬SF(nacalai tesque)を1 wellあたり10 μl加え37℃, 5%CO2のインキュベーターで2時間培養した。細胞数に比例する450 nm吸光度の測定にはGloMax-Multi+ Detection System(promega)を用いた。検量線の作製には1 mlあたり1 x 106, 3 x105,1 x 105細胞のKms12を用いた。溶媒処置時の細胞数を100とし、薬物添加時の細胞数を相対値で表した。48時間培養後の細胞数の相対値を図19に示す。
CRBNの機能がDDB1-Cul4A-Roc1 E3ユビキチンリガーゼ複合体における基質レセプターであることは支持される。CRBNと良く知られた基質レセプターであるDDB2はDDB1と競合的に結合する。第二に、CRBNは他の基質レセプターと同様に自己ユビキチン化される。DDB2を含む多くの基質レセプターがWDXR構造(motif)を有する(引用文献11,19)。一方で、少数のいくつかの基質レセプターにはそれが欠けている(引用文献13,18)。CRBNには明確なWDXRモチーフが見当たらないことから、どうも後者のタイプのようである。上記の考えを支持する結果として、CRBNおよびCul4Aのゼブラフィッシュによる発現抑制が似たような結果をもたらしたことが挙げられる。ただし、CRBNの発現抑制に比し、Cul4Aの発現抑制は形質に及ぼす影響がより深刻であった。この観察結果はそれほど驚くにはあたらない。なぜならば、CRBNを有するDDB1-Cul4Aユビキチンリガーゼはほんの少量にしか存在せず、CRBNはDDB1-Cul4Aのほんの少数の複合体にしか影響を与えられない一方で、Cul4Aの抑制はすべての複合体に影響を与えることになるからである。
(1)薬剤
サリドマイド(Tocris Cookson)の最終濃度が400mMになるようにジメチルスルホキシド(DMSO)を加え、65℃に加熱して溶解し、直ちに使用した。MG132は最終濃度10mMになるようにDMSOを加えて溶かした。実験においては陰性対照(コントロール)として同等量のDMSOを用いた。
サリドマイド固定化ビーズの作製に関する図を図6に示した。磁性FGビーズ(5mg,引用文献10)に対して10mMの1-hydroxybenzotriazole, 10mM 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide HCl,そして2mMのFR259625(carboxyl thalidomide derivative)を、溶媒であるN,N-dimethylformamide (DMF)中で4時間室温で反応させることにより、サリドマイドを固定化した。またFGビーズにおける未反応のアミノ基は20%の無水酢酸が含まれたDMF中反応させることにより保護した。完成したビーズは4℃で保存した。
サリドマイド固定化ビーズ(0.5mg)は0.5%NP-40
lysis buffer (50mM Tris HCl pH8, 150mM NaCl, 0.5% NP-40)により平衡化を行った。細胞抽出液はHeLa, Jutkat, THP-1, U266, HUVEC, LP101, SH-SY5Y, 293T由来と多岐にわたるが、それらの抽出法は文献の通りである(引用文献36)。これらの抽出液にビーズを混合し、2時間反応させた。0.5% NP-40 lysis bufferでビーズを3回洗浄した後、1mMサリドマイドによって溶出した。いくつかの実験では、0.3mMのサリドマイドをビーズとの混合前に抽出液に加えた。フタルイミドが結合するか否かについては、遊離サリドマイド1mMで溶出する過程で、代わりに1mMのフタルイミドで溶出した。
CRBNやDDB2 cDNAはRT-PCRによりHeLa total RNAから得た。CRBNの変異体は標準的なPCR法により作製した。DDB1 cDNAについてはMatsunaga博士から提供を受けた。zCrbnそしてzCul4a cDNAは24hpfにおけるゼブラフィッシュ胚のtotal RNAよりRT-PCRで得た。本研究では以下のベクターを用いた。pcDNA3.1-FH-N, pcDNA6/V5-His (Invitrogen), pFastBac1 (Invitrogen),pLenti6 (Invitrogen), pFASTBAC1 (Invitrogen), pLenti6 (Invitrogen), pCS2 (+), そしてpGEX6P-1 (GE Healthcare)。pcDNA3.1-FH-NはpcDNA3.1の派生物であり、pcDNA3.1にFLAG-HA配列を導入したものである。
CRBN抗体はヒトCRBN(65-76)を抗原としてウサギから作製したものである。FLAG (M2, Sigma), HA (3F10, Roche), V5 (V5-10, Sigma), GST (Sigma),
DDB1 (Abcam)そしてRoc1 (Zymed)は購入した。Cul4AおよびDDB2は譲渡されたものであり、それぞれRaychaudhuri博士、Matsunaga博士のご厚意による。
組み換えCRBN-FLAGおよびDDB1-V5-Hisタンパク質は昆虫Sf9細胞においてBac-to-bac (Invitrogen)バキュロウイルスシステムによって発現させ、それぞれ抗FLAG M2アガロースビーズ(Sigma)、Ni-NTAアガロースビーズ (Qiagen)により精製した。精製したCRBN-FLAG and/or DDB1-V5-Hisにサリドマイド固定化ビーズを混合し、結合タンパク質をSDS sample bufferで溶出した。CRBN欠損変異体解析においては、GST融合CRBNおよびその変異体を大腸菌であるBL21で発現させ、グルタチオンセファロースビーズ(GE helthcare)で精製した。CRBN変異体はLipofectamine 2000(Invitrogen)を用いて293T細胞に導入し過剰発現させた。そのあとの結合試験は上述と同じである。
CRBNとDDB1の間の相互作用を解析するために、CRBN-FLAGおよびDDB1-V5-HisをSf9細胞内に共発現させた。細胞抽出液に抗FLAGアガロースビーズを混合し、結合因子をFLAGペプチドで選択的に溶出した。CRBN複合体を精製するためCRBNおよびその変異体を発現する293T細胞を作製し、上述の方法でFLAG免疫精製を行った。
HAタグやV5タグ融合を用いたCRBNやDDB1を過剰発現するHeLa細胞を固定した後、抗HA抗体やV5抗体と混合させ、Alexa Fluor 594もしくは488 (Invitrogen)標識二次抗体と反応させた。
ユビキチン化試験は引用文献37を参考にして行った。FH-CRBN複合体(200ng)、Uba 1(500ng, Biomol)、UbcH5b(500ng, Biomol)、GST-Ubiquitin(4000ng,Calbiochem), 4mM ATPを30℃で2時間、15μlスケールで反応させた。反応は、SDSを加え、98℃で5分間加熱して停止させた。
この試験は引用文献38を参考にして行った。FH-CRBNもしくはその変異体を安定的に発現させた293T細胞に10μMのMG132もしくはDMSO単独(vehicle)を加え、3時間反応させた。細胞は25μMのMG132および10mMのN-ethylmaleimideを含むRIPAバッファーで溶解した。FH-CRBNを上述の方法で免疫沈降し、解析した。各濃度のサリドマイドは、MG132を処理する1時間前に加えた。
以下に示すようなStealth RNAi oligonucleotide(Invitrogen)を使用した。
DDB1 #2: 5’-CAGUAAUGAACAAGGCUCCUAUGUA-3’(配列番号2)
Cul4A #1: 5’-GCAAAGCAUGUGGAUUCAAAGUUAA-3’(配列番号3)
Cul4A #2: 5’-GAAUCUCUGAUAGACAGAGACUAUA-3’(配列番号4)
センス鎖のみ示した。コントロールとしてはStealth RNAi negative control of low GC content(Invitrogen)を用いた。Lipofectamine RNAiMAXを用いて293T細胞に40nMのオリゴヌクレオチドを導入し72時間後に細胞を回収した。
魚は28.5℃において14時間可視光明期、10時間暗期のサイクルで飼育した。
サリドマイドはDMSOに溶かした。そしてあらかじめ65℃に加熱しておいたE3培地に400μMになるように加えた。ゼブラフィッシュ胚は脱卵殻し、以下に示すようにサリドマイドに薬浴させた。2hpfにおいて胚を2mg/mlのプロテアーゼタイプ14(Sigma)に3分間反応させ、5回培地で洗浄した。その過程で脱卵殻されるが、直ちにサリドマイド含有培地に交換し、3日間観察した。サリドマイド含有培地は12時間毎に交換した。
コンドロサイトの外部マトリックスは、アルシアンブルーで染色される(引用文献40)。ゼブラフィッシュ胚は3.7%の中性ホルムアルデヒドにより一晩固定した。翌日、100%エタノールで洗浄後、PBSで再水和させた。次いで、0.05%トリプシンを含む飽和四ホウ酸ナトリウム溶液にて1-3時間反応させた。3%の過酸化水素と1%のKOH溶液により魚の斑点を除去し、70%グリセロール含有PBS溶液にて保存した。
1細胞期におけるマイクロインジェクションについては引用文献39に従って行った。我々は窒素ガス圧力マイクロインジェクター(IM 300, Narishige)を注入に使用した。CapのついたmRNAはin vitroにおいてmMESSAGE
mMACHINE in vitro transcription kit(Ambion)で作製した。
zCul4A AMO: 5’-CTGGTGCTGAACATCTTCTGCCATC-3’(配列番号6)
これらのオリゴはヌクレアーゼ除去水で700μMの濃度に調製して使用した。
この実験は引用文献41に従って行った。zcrbn mRNAのアンチセンスプローブは5’-コード領域の513bpを用いた。zcul4aについては3’UTR(3’非コード領域)の590bpを用いた。shhおよびfgf8に対応するプローブはそれぞれKrauss博士およびThisse博士のご厚意による。プローブの浸透性を増すために、胚は0.1% Tween-20および10mg/mlのproteinase Kを含んだPBSにおいて2分間常温で反応させた。
48hpfにおけるゼブラフィッシュ胚に1%メチルセルロースおよび0.003%の3-amino benzoic acid ethyl ester(Sigma)を用いて麻酔を施し、スライドグラスに乗せた。そして10個の個体を各サンプルからランダムに選び、耳胞を撮影した。サイズはNIH image Jソフトウェアを用いて計測し、コントロールの耳胞のサイズと比較した。平均値および標準偏差を計算し、p値はMann-Whitney, U検定を用いて算出した。
引用文献1:M. T. Miller, K. Stromland, Teratology 60, 306 (1999).
引用文献2:M. Melchert, A. List, Int. J. Biochem. Cell Biol. 39, 1489 (2007).
引用文献3:J. Knobloch, U. Ruther, Cell Cycle 7, 1121 (2008).
引用文献4:T. Parman, M. J. Wiley, P. G. Wells, Nat. Med. 5, 582 (1999).
引用文献5:R. J. D'Amato, M. S. Loughnan, E. Flynn, J. Folkman, Proc. Natl. Acad. Sci. U.S.A. 91, 4082 (1994).
引用文献6:J. Sheskin, Clin. Pharmacol. Ther. 6, 303 (1965).
引用文献7:S. Singhal et al., N. Engl. J. Med. 341, 1565 (1999).
引用文献8:J. B. Zeldis, B. A. Williams, S. D. Thomas, M. E. Elsayed, Clin. Ther. 21, 319 (1999).
引用文献9:S. Sakamoto, Y. Kabe, M. Hatakeyama, Y. Yamaguchi, H. Handa, Chem. Rec. 9, 66 (2009).
引用文献10:S. Sakamoto, Y. Kabe, M. Hatakeyama, Y. Yamaguchi, H. Handa, Chem. Rec. 9, 66 (2009).
引用文献11:J. J. Higgins, J. Pucilowska, R. Q. Lombardi, J. P. Rooney, Neurology 63, 1927 (2004).
引用文献12:S. Angers et al., Nature 443, 590 (2006).
引用文献13:R. Groisman et al., Cell 113, 357 (2003).
引用文献14:F. Ohtake et al., Nature 446, 562 (2007).
引用文献15:C. M. Pickart, Cell 116,181 (2004).
引用文献16:M. D. Petroski, R. J. Deshaies,Nat. Rev. Mol. Cell Biol. 6, 9 (2005).
引用文献17:K. Sugasawa et al., Cell 121, 387 (2005).
引用文献18:R. Groisman et al., Genes Dev. 20, 1429 (2006).
引用文献19:O. Leupin, S. Bontron, M. Strubin, J. Virol. 77, 6274 (2003).
引用文献20:J. Jin, E. E. Arias, J. Chen, J. W. Harper, J. C. Walter, Mol. Cell 23, 709 (2006).
引用文献21:A. Nasevicius, S. C. Ekker, Nat. Genet. 26, 216 (2000).
引用文献22:M. B. Veldman, S. Lin, Pediatr. Res. 64, 470 (2008).
引用文献23:T. Yabu et al., Blood 106, 125 (2005).
引用文献24:M. Tanaka et al., Nature 416, 527 (2002).
引用文献25:M. C. Davis, R. D. Dahn, N. H. Shubin, Nature 447, 473 (2007).
引用文献26:A. Streit, J. Anat. 199, 99 (2001).
引用文献27:R. D. Riddle, R. L. Johnson, E. Laufer, C. Tabin, Cell 75, 1401 (1993).
引用文献28:A. M. Moon, M. R. Capecchi, Nat. Genet. 26, 455 (2000).
引用文献29:M. Lewandoski, X. Sun, G. R. Martin, Nat. Genet. 26, 460 (2000).
引用文献30:A. L. Moreira et al., J. Exp. Med. 177, 1675 (1993).
引用文献31:D. Gupta et al., Leukemia 15, 1950 (2001).
引用文献32:J. Knobloch, J. D. Shaughnessy, Jr., U. Ruther, FASEB J. 21, 1410 (2007).
引用文献33:T. Kamura, C. S. Brower, R. C. Conaway, J. W. Conaway, J. Biol. Chem. 277, 30388 (2002).
引用文献34:J. M. Hansen, S. G. Gong, M. Philbert, C. Harris, Dev. Dyn. 225, 186 (2002).
引用文献35:S. Pajni-Underwood, C. P. Wilson, C. Elder, Y. Mishina, M. Lewandoski, Development 134, 2359 (2007).
引用文献36:H. Uga et al., Mol. Pharmacol. 70, 1832 (2006).
引用文献37:R. Groisman et al., Cell 113, 357 (2003).
引用文献38:F. Ohtake et al., Nature 446, 562 (2007).
引用文献39:H. Ando, T. Furuta, H. Okamoto, Methods Cell Biol. 77, 159 (2004).
引用文献40:W. L. Kelly, M. M. Bryden, Stain Technol. 58, 131 (1983).
引用文献41:C. Thisse, B. Thisse, Nat. Protoc. 3, 59 (2008).
Claims (11)
- 被験物質をセレブロンもしくはその断片と接触させ、被験物質のセレブロンもしくはその断片に対する結合性を評価し、セレブロンもしくはその断片と結合しない被験物質、又はセレブロンもしくはその断片との結合性がサリドマイドよりも低い被験物質を選択することを特徴とする非催奇性物質のスクリーニング方法。
- 被験物質が医薬であることを特徴とする請求項1に記載の非催奇性物質のスクリーニング方法。
- 被験物質が、一般式(1)
ただし、式(1)中、XがR5-R7で、YがR6-R8である場合を化合物(A)、XがR5で、YがR6-R8である場合を化合物(B)及びXがR5で、YがR8である場合を化合物(C)とし、
また、R1、R2、R3およびR4は-H;-OH;=O;直鎖および分枝アルカン、アルケン、アルキン;環式アルカン、アルケンおよびアルキン;環式ならびに非環式アルカン、アルケンおよびアルキンの組み合わせ;アルコール、アルデヒド、ケトン、カルボン酸、エステル、または環式、非環式と組み合わせたエーテル部分、あるいは環式/非環式部分の組み合わせ;アザ;アミノ;-MOnまたは-O-MOn[式中、M=Nそしてn=2;M=Sそしてn=2または3;あるいはM=Pそしてn=1-3である];そしてハロゲンから選択することができ;R5、R6、R7およびR8はそれぞれ独立して式(2)
R9は式(3)、(4)、(5)、(6)または(7)
H,-CH3,-COOH,-CONH2,-CH2)n-COOH,-(CH2)nCONH2
から選択され、n=1-4を有する部分である。 - セレブロンの断片が、配列番号7に示すアミノ酸配列において、そのN末端から339~442番目のアミノ酸配列を有し、それ以外のアミノ酸配列において1又は複数のアミノ酸残基の置換、欠失および/又は付加がなされたアミノ酸配列を有するものであることを特徴とする請求項1~3のいずれかに記載の非催奇性物質のスクリーニング方法。
- セレブロン又はその断片が、担体に固定されていることを特徴とする請求項1~4のいずれかに記載の非催奇性物質のスクリーニング方法。
- サリドマイド誘導体が、サリドマイド又は既知のサリドマイド誘導体のもつ薬理作用を持つものであることを特徴とする請求項3に記載の非催奇性物質のスクリーニング方法。
- 被験物質をセレブロン又はその断片と接触させ、被験物質とセレブロン又はその断片の結合性を調べ、セレブロン又はその断片と結合する被験物質を選択する工程、及び前記工程で選択された被験物質の中から、i)催奇性、又はii)セレブロンを含むユビキチンリガーゼ複合体の活性阻性作用を軽減する物質を選択する工程とを含むことを特徴とする催奇性物質のアンタゴニストのスクリーニング方法。
- セレブロン又はその断片が、担体に固定されていることを特徴とする請求項7に記載の催奇性物質のアンタゴニストのスクリーニング方法。
- 以下の(a)及び/又は(b)のアミノ酸置換を有することを特徴とする変異型セレブロン;
(a)ヒト由来のセレブロンにおけるN末端から384番目のチロシン若しくはこれに相当するアミノ酸がアラニンに置換されたもの
(b)ヒト由来のセレブロンにおけるN末端から386番目のトリプトファン若しくはこれに相当するアミノ酸がアラニンに置換されたもの。 - 請求項9に記載の変異型セレブロンをコードすることを特徴とする核酸。
- 請求項10に記載の核酸を遺伝子として導入し、発現させたことを特徴とするサリドマイド催奇性耐性非ヒト動物。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127008427A KR101692297B1 (ko) | 2009-10-20 | 2010-10-18 | 탈리도마이드 표적 인자를 이용한 스크리닝 방법 |
CA2774871A CA2774871C (en) | 2009-10-20 | 2010-10-18 | Screening method utilizing thalidomide-targeting factor |
US13/498,067 US9217743B2 (en) | 2009-10-20 | 2010-10-18 | Screening method utilizing thalidomide-targeting factor |
EP10824892.3A EP2492686B1 (en) | 2009-10-20 | 2010-10-18 | Screening method utilizing thalidomide-targeting factor |
RU2012120710/04A RU2528380C2 (ru) | 2009-10-20 | 2010-10-18 | Способ скрининга с использованием фактора, являющегося мишенью для талидомида |
JP2011537238A JP5660578B2 (ja) | 2009-10-20 | 2010-10-18 | サリドマイド標的因子を利用したスクリーニング方法 |
CN201080047469.0A CN102576023B (zh) | 2009-10-20 | 2010-10-18 | 利用沙利度胺靶向因子的筛选方法 |
AU2010309035A AU2010309035B2 (en) | 2009-10-20 | 2010-10-18 | Screening method utilizing thalidomide-targeting factor |
HK13100395.6A HK1173219A1 (en) | 2009-10-20 | 2013-01-10 | Screening method utilizing thalidomide-targeting factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-241290 | 2009-10-20 | ||
JP2009241290 | 2009-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011049043A1 true WO2011049043A1 (ja) | 2011-04-28 |
Family
ID=43900269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/068272 WO2011049043A1 (ja) | 2009-10-20 | 2010-10-18 | サリドマイド標的因子を利用したスクリーニング方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9217743B2 (ja) |
EP (1) | EP2492686B1 (ja) |
JP (1) | JP5660578B2 (ja) |
KR (1) | KR101692297B1 (ja) |
CN (1) | CN102576023B (ja) |
AU (1) | AU2010309035B2 (ja) |
CA (1) | CA2774871C (ja) |
HK (1) | HK1173219A1 (ja) |
HU (1) | HUE039781T2 (ja) |
RU (1) | RU2528380C2 (ja) |
WO (1) | WO2011049043A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014004990A2 (en) * | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
US9611465B2 (en) | 2009-05-25 | 2017-04-04 | Celgene Corporation | Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell |
JP2017528690A (ja) * | 2014-06-27 | 2017-09-28 | セルジーン コーポレイション | セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028445A2 (en) * | 2012-08-14 | 2014-02-20 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
EP2757379A1 (en) | 2013-01-16 | 2014-07-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method to screen for the teratogenic potential of substances |
KR20140100731A (ko) * | 2013-02-07 | 2014-08-18 | 광주과학기술원 | Crb n ko 마우스의 제조방법 및 이의 용도 |
WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
CA3206268A1 (en) * | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
EP3347717A4 (en) | 2015-09-11 | 2019-06-05 | The Brigham and Women's Hospital, Inc. | METHODS OF CHARACTERIZING RESISTANCE TO CERTIFIED MODULATORS |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
US20200348285A1 (en) * | 2017-11-09 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Methods to prevent teratogenicity of imid like molecules and imid based degraders/protacs |
EP3830093A1 (en) | 2018-07-27 | 2021-06-09 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
US10844039B2 (en) | 2018-11-13 | 2020-11-24 | Biotheryx, Inc. | Substituted isoindolinones |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN111678756A (zh) * | 2020-06-12 | 2020-09-18 | 苏州木芮生物科技有限公司 | 斑马鱼软骨染色一步法试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893071B2 (en) * | 2001-04-23 | 2011-02-22 | University Of Virginia Patent Foundation | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic |
AU2004288714A1 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
CN1696127A (zh) * | 2005-04-18 | 2005-11-16 | 中国科学院长春应用化学研究所 | 沙利度胺的类似物及其制备方法 |
JPWO2007097109A1 (ja) * | 2006-02-20 | 2009-07-09 | 国立大学法人 東京医科歯科大学 | 抗関節リウマチ活性を有する物質のスクリーニング方法及び評価方法 |
CN101017166A (zh) * | 2007-01-18 | 2007-08-15 | 复旦大学 | 人rtn4b蛋白在制备抗肿瘤药物中的应用 |
KR100901128B1 (ko) * | 2007-07-10 | 2009-06-04 | 한국과학기술연구원 | 탈리도마이드 처리에 따른, 최기형성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법 |
KR100974228B1 (ko) * | 2007-11-16 | 2010-08-06 | 한국과학기술연구원 | 최기형성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 최기형성 및 부작용 유발 약물 검색 방법 |
-
2010
- 2010-10-18 US US13/498,067 patent/US9217743B2/en not_active Expired - Fee Related
- 2010-10-18 CN CN201080047469.0A patent/CN102576023B/zh active Active
- 2010-10-18 KR KR1020127008427A patent/KR101692297B1/ko active IP Right Grant
- 2010-10-18 JP JP2011537238A patent/JP5660578B2/ja not_active Expired - Fee Related
- 2010-10-18 AU AU2010309035A patent/AU2010309035B2/en not_active Ceased
- 2010-10-18 RU RU2012120710/04A patent/RU2528380C2/ru active
- 2010-10-18 WO PCT/JP2010/068272 patent/WO2011049043A1/ja active Application Filing
- 2010-10-18 HU HUE10824892A patent/HUE039781T2/hu unknown
- 2010-10-18 CA CA2774871A patent/CA2774871C/en active Active
- 2010-10-18 EP EP10824892.3A patent/EP2492686B1/en active Active
-
2013
- 2013-01-10 HK HK13100395.6A patent/HK1173219A1/xx not_active IP Right Cessation
Non-Patent Citations (49)
Title |
---|
"Proceedings of the Guadeloupe CoNF. "METHODS DETECT ENVIRON AGENTS THAT PROD CONGENITAL DEFECTS"", 1975, article SCHUMACHER, H.J.: "Chemical structure and teratogenic properties.", pages: 65 - 77, XP008159001 * |
"Proceedings of the Guadeloupe Conf. "Methods Detect Environ Agents That Prod Congenital Defects"", 1975, article ZIMMERMAN, E.F.: "Chemical structure and teratogenic mechanism of action.", pages: 79 - 88, XP008158952 * |
0. LEUPIN; S. BONTRON; M. STRUBIN, J. VIROL., vol. 77, 2003, pages 6274 |
A. L. MOREIRA ET AL., J. EXP. MED., vol. 177, 1993, pages 1675 |
A. M. MOON; M. R. CAPECCHI, NAT. GENET., vol. 26, 2000, pages 455 |
A. NASEVICIUS; S. C. EKKER, NAT. GENET., vol. 26, 2000, pages 216 |
A. STREIT, J. ANAT., vol. 199, 2001, pages 99 |
AIZAWA, M. ET AL.: "mRNA distribution of the thalidomide receptor, cereblon, in adult rat brain", BULLETINOF THE JAPANESE SOCIETY FOR NEUROCHEMISTRY, vol. 49, no. 2/3, 1 August 2010 (2010-08-01), pages 589, XP008158987 * |
AKIRA MURAKAMI: "Around the functional food 54) Thalidomide no Hyoteki Bunshi", FOOD STYLE 21, vol. 14, no. 9, 1 September 2010 (2010-09-01), pages 66 - 67, XP008159027 * |
C. M. PICKART, CELL, vol. 116, 2004, pages 181 |
C. THISSE; B. THISSE, NAT. PROTOC., vol. 3, 2008, pages 59 |
D. GUPTA ET AL., LEUKEMIA, vol. 15, 2001, pages 1950 |
F. OHTAKE ET AL., NATURE, vol. 446, 2007, pages 562 |
FICKENTSCHER, K. ET AL.: "Teratogenicity and embryotoxicity of thalidomide and 3-aza- thalidomide in mice.", PHARMACOLOGY, vol. 11, no. 4, 1974, pages 193 - 198, XP008158986 * |
H. ANDO; T. FURUTA; H. OKAMOTO, METHODS CELL BIOL., vol. 77, 2004, pages 159 |
H. UGA ET AL., MOL. PHARMACOL., vol. 70, 2006, pages 1832 |
HIDEKI ANDO ET AL.: "Thalidomide Saikisei, Hyoteki Inshi no Dotei", CELL TECHNOLOGY, vol. 29, no. 8, 22 July 2010 (2010-07-22), pages 812 - 813, XP008158936 * |
HOHBERGER, B. ET AL.: "Cereblon is expressed in the retina and binds to voltage-gated chloride channels", FEBS LETT., vol. 583, no. 4, 21 January 2009 (2009-01-21), pages 633 - 637, XP025947012 * |
ITO, T. ET AL.: "Identification of a Primary Target of Thalidomide Teratogenicity", SCIENCE, vol. 327, no. 5971, 12 March 2010 (2010-03-12), pages 1345 - 1350, XP055041158 * |
J. B. ZELDIS; B. A. WILLIAMS; S. D. THOMAS; M. E. ELSAYED, CLIN. THER., vol. 21, 1999, pages 319 |
J. J. HIGGINS; J. PUCILOWSKA; R. Q. LOMBARDI; J. P. ROONEY, NEUROLOGY, vol. 63, 2004, pages 1927 |
J. JIN; E. E. ARIAS; J. CHEN; J. W. HARPER; J. C. WALTER, MOL. CELL, vol. 23, 2006, pages 709 |
J. KNOBLOCH; J. D. SHAUGHNESSY, JR.; U. RUTHER, FASEB J., vol. 21, 2007, pages 1410 |
J. KNOBLOCH; U. RUTHER, CELL CYCLE, vol. 7, 2008, pages 1121 |
J. M. HANSEN; S. G. GONG; M. PHILBERT; C. HARRIS, DEV. DYN., vol. 225, 2002, pages 186 |
J. SHESKIN, CLIN. PHARMACOL. THER., vol. 6, 1965, pages 303 |
K. SUGASAWA ET AL., CELL, vol. 121, 2005, pages 387 |
KAWAGUCHI ET AL., NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 6229 - 6240 |
M. B. VELDMAN; S. LIN, PEDIATR. RES., vol. 64, 2008, pages 470 |
M. C. DAVIS; R. D. DAHN; N. H. SHUBIN, NATURE, vol. 447, 2007, pages 473 |
M. D. PETROSKI; R. J. DESHAIES, NAT. REV. MOL. CELL BIOL., vol. 6, 2005, pages 9 |
M. LEWANDOSKI; X. SUN; G. R. MARTIN, NAT. GENET., vol. 26, 2000, pages 460 |
M. MELCHERT; A. LIST, INT. J. BIOCHEM. CELL BIOL., vol. 39, 2007, pages 1489 |
M. T. MILLER; K. STROMLAND, TERATOLOGY, vol. 60, 1999, pages 306 |
M. TANAKA ET AL., NATURE, vol. 416, 2002, pages 527 |
NISHIO ET AL., COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 64, 2008, pages 162 - 169 |
R. D. RIDDLE; R. L. JOHNSON; E. LAUFER; C. TABIN, CELL, vol. 75, 1993, pages 1401 |
R. GROISMAN ET AL., CELL, vol. 113, 2003, pages 357 |
R. GROISMAN ET AL., GENES DEV., vol. 20, 2006, pages 1429 |
R. J. D'AMATO; M. S. LOUGHNAN; E. FLYNN; J. FOLKMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 91, 1994, pages 4082 |
S. ANGERS ET AL., NATURE, vol. 443, 2006, pages 590 |
S. PAJNI-UNDERWOOD; C. P. WILSON; C. ELDER; Y. MISHINA; M. LEWANDOSKI, DEVELOPMENT, vol. 134, 2007, pages 2359 |
S. SAKAMOTO; Y. KABE; M. HATAKEYAMA; Y. YAMAGUCHI; H. HANDA, CHEM. REC., vol. 9, 2009, pages 66 |
S. SINGHAL ET AL., N. ENGL. J. MED., vol. 341, 1999, pages 1565 |
T. KAMURA; C. S. BROWER; R. C. CONAWAY; J. W. CONAWAY, J. BIOL. CHEM., vol. 277, 2002, pages 30388 |
T. PARMAN; M. J. WILEY; P. G. WELLS, NAT. MED., vol. 5, 1999, pages 582 |
T. YABU ET AL., BLOOD, vol. 106, 2005, pages 125 |
TAKUMI ITO ET AL.: "Tsuini Kaimei! Thalidomide ga Okosu Saikisei no Nazo Hyoteki Bunshi Cereblon o Tsukitometa FG Beads", CHEMISTRY, vol. 65, no. 8, 1 August 2010 (2010-08-01), pages 47 - 51, XP008159289 * |
W. L. KELLY; M. M. BRYDEN, STAIN TECHNOL., vol. 58, 1983, pages 131 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9611465B2 (en) | 2009-05-25 | 2017-04-04 | Celgene Corporation | Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell |
US10047151B2 (en) | 2011-04-29 | 2018-08-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
JP2014514579A (ja) * | 2011-04-29 | 2014-06-19 | セルジーン コーポレイション | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
US9365640B2 (en) | 2011-04-29 | 2016-06-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
JP2017037081A (ja) * | 2011-04-29 | 2017-02-16 | セルジーン コーポレイション | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
WO2014004990A3 (en) * | 2012-06-29 | 2014-06-12 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
WO2014004990A2 (en) * | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US9857359B2 (en) | 2012-06-29 | 2018-01-02 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
JP2017528690A (ja) * | 2014-06-27 | 2017-09-28 | セルジーン コーポレイション | セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
US10092555B2 (en) | 2014-06-27 | 2018-10-09 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US10668057B2 (en) | 2014-06-27 | 2020-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US11419861B2 (en) | 2014-06-27 | 2022-08-23 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US11733233B2 (en) | 2015-12-28 | 2023-08-22 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
Also Published As
Publication number | Publication date |
---|---|
CA2774871A1 (en) | 2011-04-28 |
HUE039781T2 (hu) | 2019-02-28 |
KR20120093852A (ko) | 2012-08-23 |
US9217743B2 (en) | 2015-12-22 |
KR101692297B1 (ko) | 2017-01-04 |
AU2010309035A1 (en) | 2012-04-12 |
EP2492686A4 (en) | 2013-07-17 |
US20120192297A1 (en) | 2012-07-26 |
RU2012120710A (ru) | 2013-11-27 |
EP2492686B1 (en) | 2018-06-13 |
HK1173219A1 (en) | 2013-05-10 |
JP5660578B2 (ja) | 2015-01-28 |
CA2774871C (en) | 2018-05-29 |
CN102576023A (zh) | 2012-07-11 |
JPWO2011049043A1 (ja) | 2013-03-14 |
AU2010309035B2 (en) | 2014-01-30 |
RU2528380C2 (ru) | 2014-09-20 |
EP2492686A1 (en) | 2012-08-29 |
CN102576023B (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5660578B2 (ja) | サリドマイド標的因子を利用したスクリーニング方法 | |
Asatsuma-Okumura et al. | p63 is a cereblon substrate involved in thalidomide teratogenicity | |
Warren et al. | Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human | |
Watson et al. | Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span | |
Zhao et al. | piRNA-triggered MIWI ubiquitination and removal by APC/C in late spermatogenesis | |
Iwata et al. | Modulation of noncanonical TGF-β signaling prevents cleft palate in Tgfbr2 mutant mice | |
Che et al. | TDP-35 sequesters TDP-43 into cytoplasmic inclusions through binding with RNA | |
Vernon et al. | Slug stability is dynamically regulated during neural crest development by the F-box protein Ppa | |
Kim et al. | CK2 is a novel negative regulator of NADPH oxidase and a neuroprotectant in mice after cerebral ischemia | |
US20120296403A1 (en) | Methods and compounds for muscle growth | |
Zhang et al. | Novel RNA-and FMRP-binding protein TRF2-S regulates axonal mRNA transport and presynaptic plasticity | |
Aripaka et al. | TRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancer | |
Yokoi et al. | Two mammalian homologs of yeast Rad23, HR23A and HR23B, as multifunctional proteins | |
JP2010531662A (ja) | P53のモジュレータ及び癌の標的であるtrim24(tif−1a) | |
Han et al. | Ubiquitin C-terminal hydrolase37 regulates Tcf7 DNA binding for the activation of Wnt signalling | |
Pluciennik et al. | Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy | |
Sevcik et al. | Expression of human BRCA1Δ17–19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response | |
Tu et al. | RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma | |
US20170355997A1 (en) | Methods and compositions for treating or preventing pruritis | |
Yu et al. | Zebrafish Nedd8 facilitates ovarian development and the maintenance of female secondary sexual characteristics via suppression of androgen receptor activity | |
Kreissl et al. | Molecular methods to study protein trafficking between organs | |
Ishihara et al. | Lens epithelium‐derived growth factor deSumoylation by Sumo‐specific protease‐1 regulates its transcriptional activation of small heat shock protein and the cellular response | |
Parameswaran et al. | Antisense, but not sense, repeat expanded RNAs activate PKR/eIF2α-dependent integrated stress response in C9orf72 FTD/ALS | |
JP6882199B2 (ja) | Usp4阻害剤を用いたスクリーニングおよび処置の方法 | |
Longman et al. | Identification of a nonsense-mediated decay pathway at the endoplasmic reticulum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080047469.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10824892 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011537238 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010309035 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2774871 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13498067 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010824892 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127008427 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2010309035 Country of ref document: AU Date of ref document: 20101018 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3365/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012120710 Country of ref document: RU |